Bone Cancer: Pharmacologic Management
Primary bone cancers are rare cancers that arise from primitive mesenchymal cells from which all connective tissues are derived. Bone cancer accounts for 0.2% of all cancers.
Cancer Management
Cancer Therapy Advisor’s cancer treatment resources now include the most recent guideline-based information to inform oncologists and oncology professionals about therapy selection for optimal patient outcomes. These articles provide accurate and up-to-date information about FDA-approved therapies commonly recommended in cancer treatment guidelines for different types of cancer, recent updates to US guidelines for cancer treatment, and adverse events and drug-drug interactions associated with certain therapies.
Don’t see the specific treatment guidance you need?
As we roll out resources for other cancer types, sign up to be notified via email when new cancer treatment guidelines are added.
Anal Cancer: Pharmacologic Management
Anal cancer, of which fewer than 10,000 patients are diagnosed annually in the United States, is an uncommon type of cancer occurring in the tissue of the anus.
Small Cell Lung Cancer: Pharmacologic Management
Small cell lung cancer (SCLC) accounts for approximately 14% of lung and bronchus cancers, with approximately 30,000 to 35,000 new cases diagnosed in the United States each year.
Testicular Cancer: Pharmacologic Management
Testicular cancer is the most common solid tumor diagnosed in US men aged 20 to 34 years,1 and it is diagnosed with decreasing frequency as men age.
Gastric Cancer: Pharmacologic Management
Gastric cancer is the fifth most common malignant cancer and the fourth leading cause of cancer-related mortality globally.
Prostate Cancer: Pharmacologic Management
In the United States, prostate cancer is the most frequent cancer diagnosed in men and the second most common cause of cancer fatalities.
Pancreatic Cancer: Pharmacologic Management
Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent pancreatic malignancy. This condition represents approximately 3% of all cancers in the United States and approximately 7% of all cancer deaths.
Metastatic Breast Cancer: Pharmacologic Management
Breast cancer is the most common type of cancer, with an estimated 300,590 new cases in the United States in 2023. The National Cancer Institute also estimates that breast cancer will account for 43,170 to 43,530 new deaths in 2023.
Multiple Myeloma: Pharmacologic Management
Multiple myeloma is a malignancy of the plasma cells. Multiple myeloma develops when clonal plasma cells proliferate in the bone marrow or form extramedullary plasmacytomas.
Non-Hodgkin Lymphoma: Pharmacologic Management
Non-Hodgkin lymphoma (NHL) consists of a diverse group of lymphomas that originate in the lymphoid tissues and spread throughout the body.
Esophageal Cancer: Pharmacologic Management
Esophageal cancer accounts for 1.1% of all cancer cases and is the 11th leading cause of cancer death in the United States.
Acute Lymphoblastic Leukemia: Pharmacologic Management
Acute lymphoblastic leukemia (ALL) is the most prevalent pediatric leukemia and makes up one-quarter of cancer cases among adolescents and children younger than 15 years.
Breast Cancer: Pharmacologic Management
The National Cancer Institute estimates that there will be 297,790 new cases of invasive breast cancer and 55,720 new cases of ductal carcinoma in situ (DCIS) diagnosed in 2023.
Ovarian Cancer: Pharmacologic Treatment
Among gynecologic cancers, ovarian cancer is associated with the most deaths and is the fifth most frequent cause of death overall in women.
Bladder Cancer Guidelines
The best bladder cancer treatment option may include more than one type or combination of different treatments (chemotherapy, radiation, and surgery).
Non-Small Cell Lung Cancer: Pharmacologic Treatment
Lung cancer is the second most common cancer in the United States and estimated to account for 12.2% of new cancer cases in 2023.
Colorectal Cancer: Pharmacologic Management
Colorectal cancer is the third most common cancer and the second leading cause of cancer death in the United States.1 Colorectal cancer is an umbrella term that refers to cancer of both the colon and the rectum.
Head and Neck Cancer: Treatment & Management
Head and neck cancer is the seventh most common cancer worldwide2 and accounts for approximately 4% of all cancers in the United States.
Hodgkin Lymphoma: Pharmacologic Treatment
Hodgkin lymphoma (formerly known as Hodgkin’s disease) is a rare type of lymphoma that accounts for only 0.5% of all new cancer cases in the United States.
Bladder Cancer: Pharmacologic Management
Bladder cancer is the sixth most prevalent cancer in the United States. As of 2023, 82,290 new diagnoses of bladder cancer (62,420 in men and 19,870 in women) were documented, as well as 16,710 deaths.
Endometrial Cancer: Pharmacologic Management
Endometrial cancer is the most common type of gynecologic cancer in the United States, with approximately 66,000 new cases diagnosed in 2023.
Colon Cancer Guidelines
Colon cancer is the third most common cancer diagnosed in the United States. The overall lifetime risk of developing colorectal cancer is approximately 1 in 23 for men and 1 in 25 in women. Learn more about the staging, management, and prognosis of colon cancer.
Renal Cell Carcinoma Guidelines
Renal Cell Carcinoma is the 10th most common cancer. Most renal cancers arise from the epithelial tubules of the nephron. This reference covers risk factors, testing, prognosis, and treatments.
Prostate Cancer Guidelines
Prostate cancer is the second most common type of cancer, and cancer death, in men in the United States with an estimated annual incidence of 268,490 cases and an estimated 34,500 deaths each year.
Pheochromocytoma Diagnosis & Treatment
Pheochromocytoma is a rare neuroendocrine disorder in which a tumor grows within the adrenal medulla. This tumor causes the continuous overproduction of epinephrine and norepinephrine, which, if left without treatment, can lead to severe or life-threatening damage to other body systems.
Pituitary Adenoma and Pregnancy
Pituitary adenomas are typically prolactinomas, which are the most frequent cause of elevated prolactin levels. Pituitary adenomas comprise over 85% of pituitary tumors, and 25% to 30% of these are hormonally inactive. The incidence of prolactinomas is four times greater in women than in men.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...